Back to today’s briefing

Story perspectives

Biogen/Ionis Drug Slashes Tau 60%, Shares Drop 7%

7/14/2026

29 6 Full Breakdown

Summary

Biogen Slows Decline

Biogen and Ionis said diranersen lowered tau and slowed cognitive decline in a Phase 2 trial.
In the 18-month CELIA study of 416 early-Alzheimer’s patients, the 60 mg dose cut tau by 50-65% and slowed decline by 26% on the CDR-SB scale.
The trial missed its primary dose-response goal because the lowest dose showed the greatest benefit.
Biogen shares fell about 7% and Ionis shares dropped roughly 2.5% after the release.

Summary

NIH Anti-Tau Trial

NIH-funded Alzheimer’s Tau Platform will test anti-tau therapies such as vaccine AADvac1 at multiple U.S. sites and later enroll pre-symptomatic participants.
NewAmsterdam Pharma will study obicetrapib to see if the cholesterol-lowering drug reduces Alzheimer’s protein buildup in APOE4 carriers.
Denali Therapeutics CEO Ryan Watts says its iron-hitchhiking method seeks to improve brain delivery of tau and amyloid drugs.

1 of 2

Biogen Slows Decline

Biogen and Ionis said diranersen lowered tau and slowed cognitive decline in a Phase 2 trial.
In the 18-month CELIA study of 416 early-Alzheimer’s patients, the 60 mg dose cut tau by 50-65% and slowed decline by 26% on the CDR-SB scale.
The trial missed its primary dose-response goal because the lowest dose showed the greatest benefit.
Biogen shares fell about 7% and Ionis shares dropped roughly 2.5% after the release.

1 / 2